Cadrenal Therapeutics grants Golden 75,000 options

The options were fully vested and immediately exercisable on the grant date and expire on October 8, 2036.

Rhea-AI Filing Summary

Cadrenal Therapeutics, Inc. director Lee Scott Golden was granted 75,000 stock options on October 9, 2026, under the company’s 2022 Successor Equity Incentive Plan. The options were fully vested and immediately exercisable on the grant date, with an exercise price of $0.91 per share and an expiration date of October 8, 2036. They cover 75,000 shares of common stock, and the exercise price equaled the closing price of the company’s common stock on the grant date.

Insider Trade Summary

Grant/Award: 75,000 shares

Grant/Award 1 txn

Insider Golden Lee Scott

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option F1	75,000	$0.00	$0.00

Holdings After Transaction: Stock Option — 75,000 contracts (Direct)

Footnotes (1)

1. F1. The stock options have a grant date of October 9, 2026 under the Issuer's 2022 Successor Equity Incentive Plan, were fully vested and immediately exercisable on the date of grant, and have an exercise price equal to the closing price of the Issuer's common stock on October 9, 2026.

Key Figures

Stock options granted: 75,000 options Exercise price: $0.91 per share Underlying common stock: 75,000 shares +1 more

4 metrics

Stock options granted 75,000 options Granted October 9, 2026

Exercise price $0.91 per share Equal to the closing price of the company’s common stock on October 9, 2026

Underlying common stock 75,000 shares Shares covered by the options

Expiration date October 8, 2036 Stock options

Key Terms

fully vested, immediately exercisable, exercise price, 2022 Successor Equity Incentive Plan

4 terms

fully vested financial

"were fully vested and immediately exercisable"

immediately exercisable financial

"fully vested and immediately exercisable on the date of grant"

exercise price financial

"have an exercise price equal to the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

2022 Successor Equity Incentive Plan financial

"under the Issuer's 2022 Successor Equity Incentive Plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CVKD options did director Lee Scott Golden receive?

Lee Scott Golden received 75,000 stock options on October 9, 2026. They were fully vested and immediately exercisable on the grant date, carry a $0.91 exercise price per share, and expire on October 8, 2036. The options cover 75,000 shares of common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/13/2026 - 05:33 PM EDT Accepted by SEC EDGAR 10/13/2026 - 05:33 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Golden Lee Scott

(Last) (First) (Middle)

C/O CADRENAL THERAPEUTICS, INC.

822 A1A NORTH, SUITE 306

(Street)

PONTE VEDRA FLORIDA 32082

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cadrenal Therapeutics, Inc. [ CVKD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$0.91	10/09/2026		A		75,000(1)		10/09/2026(1)	10/08/2036	Common Stock	75,000	$0	75,000	D

Explanation of Responses:

1. The stock options have a grant date of October 9, 2026 under the Issuer's 2022 Successor Equity Incentive Plan, were fully vested and immediately exercisable on the date of grant, and have an exercise price equal to the closing price of the Issuer's common stock on October 9, 2026.

	/s/ Quang X. Pham, Attorney-in-fact	10/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)